Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Shares Lifted by Prospect of Gilenya Exclusivity in US -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 12:53pm EDT

By Donato Paolo Mancini

Novartis AG's (NOVN.EB) closed higher on Thursday after jumping on news of a ruling that suggested that market exclusivity for the company's multiple-sclerosis blockbuster drug Gilenya in the U.S. will likely be extended.

"A favorable resolution of the dosage regimen patent litigation" may lengthen the period in which the drug is free from generic competition, according to a Novartis document seen by Dow Jones Newswires.

The note was sent out at around midday Thursday, two analysts told Dow Jones, and shares started climbing around that time. One of the analysts said the market wasn't expecting the decision, so that sent the share price up.

According to the document, the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office issued a decision upholding the validity of the dosage-regimen patent on Wednesday. The decision can be appealed, the document said.

Gilenya had sales of $3.19 billion in 2017, according to the company's annual report.

Novartis said it was pleased with the decision, and that it expected to maintain exclusivity until August 2019.

Shares closed up 4.1% at CHF78.94.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07:13pSTATEMENT OF CHANGES IN BENEFICIAL O : 0000925421-19-000157 (34 Act) Size: 11 KB
PU
09:08aGLOBAL MARKETS LIVE : Samsung, Wirecard, Boeing, Nissan…
06:16aAMGEN : Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook
RE
06:07aNOVARTIS : Earnings Bolster CEO's Revamp Efforts--Update
DJ
05:48aNOVARTIS : 1Q Earnings Snapshot
AQ
03:52aNovartis Shares Buoyed by Guidance Hike -- Update
DJ
01:35aNOVARTIS : Sales Rose in 1Q
DJ
01:01aNOVARTIS : starts 2019 with strong sales and double digit core operating income ..
AQ
04/23Global Stocks Weaken as Oil Prices Climb
DJ
04/18NOVARTIS : FDA accepts Novartiss BLA for brolucizumab for treatment of wet AMD
AQ
More news
Financials ($)
Sales 2019 49 547 M
EBIT 2019 12 924 M
Net income 2019 8 537 M
Debt 2019 14 000 M
Yield 2019 3,83%
P/E ratio 2019 19,72
P/E ratio 2020 17,76
EV / Sales 2019 4,23x
EV / Sales 2020 4,00x
Capitalization 196 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,5 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS4.88%195 750
JOHNSON & JOHNSON6.80%372 522
ROCHE HOLDING LTD.10.11%227 132
PFIZER-9.69%218 852
MERCK AND COMPANY-2.37%192 697
ELI LILLY AND COMPANY1.53%121 698